Synergistic interactions between 12-0-tetradecanoylphorbol-13-acetate (TPA) and imatinib in patients with chronic myeloid leukemia in blastic phase that is resistant to standard-dose imatinib
Keywords: 12-0-تتراداکانویلوروربول-13-استات; Chronic myelogenous leukemia; Blastic phase; 12-0-Tetradecanoylphorbol-13-acetate; Imatinib; Resistant